Acadia Pharmaceuticals Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.56B
↑+31.7% +$376Mvs FY2024
Total Liabilities
$337M
↓-26.0% -$118Mvs FY2024
Equity
$1.23B
↑+67.5% +$495Mvs FY2024
Cash
$178M
↓-44.4% -$142Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.56B | $1.19B |
| Current Assets | $1.06B | $938M |
| Cash | $178M | $320M |
| ST Investments | $0 | $0 |
| Receivables | $121M | $99M |
| Inventory | $111M | $92M |
| Other Current | $652M | $428M |
| Non-Current Assets | $502M | $249M |
| PPE | $8M | $4M |
| Goodwill | $0 | $0 |
| Intangibles | $109M | $120M |
| Investments | $0 | $0 |
| Other Non-Current | $386M | $125M |
| Total Liab+Eq | $1.56B | $1.19B |
| Current Liab. | $277M | $395M |
| Accounts Payable | $11M | $16M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $266M | $379M |
| Non-Current Liab. | $60M | $60M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $60M | $60M |
| Equity | $1.23B | $733M |
| Retained Earnings | $1.81B | $2.20B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · ACAD · Comparing FY2025 vs FY2024